Annexon, Inc. Stock Price, News & Analysis

Annexon, a clinical-stage biopharma, reported Q3 2022 results with a net loss of $35.1 million ($0.51 per share), an improvement from $35.6 million ($0.93 per share) a year earlier. Cash reserves are $269.5 million, sufficient to fund operations into H2 2025. The company is advancing trials for its complement-targeted therapies, including late-stage studies for ANX005 in Guillain-Barré Syndrome and Huntington’s disease. Upcoming presentations at scientific conferences will showcase its novel approaches and preclinical progress on ANX007 for geographic atrophy.

Annexon, Inc. (Nasdaq: ANNX) announced the granting of equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan. The awards, approved on October 17, 2022, involve options to purchase 87,400 shares of common stock, with an exercise price of $5.63 per share, reflecting the closing stock price on the grant date. The options have a ten-year term and vest over four years. Annexon focuses on developing complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders.

Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, announced the granting of equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan. This decision, made on September 15, 2022, complies with Nasdaq Listing Rule 5635(c)(4). The new employees received options to purchase a total of 125,000 shares of common stock, at an exercise price of $6.34 per share. The options have a ten-year term and will vest over four years, with the first 25% vesting on the first anniversary of their employment.

Annexon, Inc. (Nasdaq: ANNX) announced the granting of equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan. Approved on August 16, 2022, the awards total 172,000 shares of common stock in options with a ten-year term and an exercise price of $5.83. Vesting will occur over four years, starting 25% on the first anniversary of employment. Annexon is dedicated to developing innovative complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders.

Annexon, a clinical-stage biopharmaceutical company focused on complement-mediated diseases, reported significant progress with five clinical-stage candidates following recent Phase 1 trial initiations for ANX105 and ANX1502. The company secured approximately $130 million in a private placement, extending its operating runway into the second half of 2025. The FDA granted Fast Track designation for ANX007 targeting geographic atrophy. Despite a net loss of $37.1 million in Q2 2022, the promising pipeline and anticipated clinical milestones are set to drive future growth.

Annexon, Inc. (Nasdaq: ANNX) has completed a private placement, raising approximately $130 million to support its clinical pipeline of complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders. This funding will extend the company’s operational runway into the second half of 2025. The placement includes the sale of 9,013,834 shares and pre-funded warrants at prices around $3.87 per share. Major investors include Redmile Group, Adage Capital, and Bain Capital. Annexon aims to advance its first oral complement agent, ANX1502.

Annexon, a clinical-stage biopharmaceutical company, announced a private placement expected to raise approximately $130 million before fees. The placement involves selling 9,013,834 shares of common stock and warrants, priced at $3.871250 per share. Major investors include Redmile Group and Adage Capital. The deal will close on July 11, 2022, pending customary conditions. The company is committed to filing a registration statement for resale of the shares, aligning with Nasdaq regulations.

Annexon (Nasdaq: ANNX) announced positive final data from its Phase 2 clinical trial of ANX005 for Huntington’s disease (HD), showing complete C1q target inhibition and stabilization of disease progression over nine months. Of 28 participants, 23 completed the study, demonstrating sustained clinical benefits in patients with high baseline complement activity. The treatment was generally well-tolerated, with no serious adverse events reported. These results highlight ANX005’s potential as a novel therapy for HD, addressing a critical unmet need in the field.

Annexon (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, announced that CEO Douglas Love will present at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 10:30 a.m. ET in New York City. The event is part of Annexon's effort to showcase its innovative complement medicines targeting autoimmune, neurodegenerative, and ophthalmic disorders. A live webcast will be available on the company's Investors page, with a 30-day replay option.

Annexon is developing a diverse pipeline aimed at treating classical complement-mediated diseases.